M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal BioSpaceOf the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb.OncologyRead full story pharminent May 12, 2026 (Last updated: May 12, 2026) BioSpace Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billionNext: Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug Related Stories M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy pharminent June 22, 2026 M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech pharminent June 22, 2026 M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance pharminent June 22, 2026
